Loading...
Men with high-risk non-metastatic prostate cancer are frequently managed with external beam radiotherapy (EBRT) along with two to three years of androgen deprivation therapy (ADT). In the metastatic setting, there is compelling evidence from phase 3 trials of an overall survival benefit from ADT intensification with docetaxel or next-generation hormonal therapy agents (abiraterone, enzalutamide, and apalutamide); data in the high-risk locally advanced setting are more limited.
In a meta-analysis, investigators pooled data from two prospective, randomized, phase 3 STAMPEDE trials that compared ADT for three years to either ADT plus abiraterone acetate or ADT plus abiraterone acetate plus enzalutamide for two years in men with locally advanced…